AbbVie Inc $50.14

up +0.13


23/4/2014 06:40 PM  |  NYSE : ABBV  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get ABBV Trend Analysis - it has underperformed the S&P 500 by 8%

Partner Headlines

  1. Gilead, Illumina Q1 Earnings Win Wall Street's Love

    IBD
  2. Gilead Sovaldi Drug Sales Key In Q1 Earnings Report

    IBD
  3. Gilead Q1 Its First Full Quarter With Sovaldi

    IBD
  4. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  5. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  6. AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) ...

    Benzinga
  7. Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

    Benzinga
  8. Benzinga's Top #PreMarket Losers

    Benzinga
  9. HCV Rivalry Heats Up As Merck Combo Shines In Trial

    IBD
  10. Merck Hepatitis C Combo Scores 98% Cure Rate

    IBD
  11. UPDATE: Morgan Stanley Reiterates, Removes PT on AbbVie on Potential of ...

    Benzinga
  12. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  13. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  14. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  15. TripAdvisor: Yelp of Travel Looks Too Pricey

    YCharts
  16. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  17. House Probe Of Gilead's Sovaldi Price Hits Biotechs

    IBD
  18. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  19. Lountzis Asset Management Comments on Abbvie

    GuruFocus
  20. Gilead Pricing Probed By House; Biotech Stocks Drop

    IBD
  21. Gilead's HCV Challengers Near The Starting Gate

    IBD
  22. Gilead's HCV Challengers Near The Starting Gate

    IBD
  23. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  24. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  25. Pharma Patent Cliff: Why Worst Seems Over

    YCharts
  26. UPDATE: Bank of America Reiterates on AbbVie on Higher HCV Sales

    Benzinga
  27. Investors Brace for Bear Market

    FoxBusiness
  28. AbbVie’s Testosterone: Impact of Health Concerns

    YCharts
  29. #PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over ...

    Benzinga
  30. Earnings Scheduled For January 31, 2014

    Benzinga
  31. We Were Dividends, Before Dividends Were Cool

    GuruFocus
  32. Abbott Labs Q4 Sales Miss Estimates; Earnings In Line

    IBD
  33. AbbVie Initiates Pivotal Phase 3 Study of Veliparib for Patients with Early-Stage ...

    Benzinga
  34. Enanta Joins Big Leagues With Hepatitis C Drug

    IBD
  35. BofA Merrill Lynch Reiterates on AbbVie, Raises PO

    Benzinga
  36. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  37. Drugmaker Aptalis Files For IPO After Overhaul

    IBD
  38. Benzinga's Top Downgrades

    Benzinga
  39. S&P Stocks Hitting New Highs

    FoxBusiness
  40. Co-Pays: Skin In the Game If It Ain’t Your Skin?

    YCharts
  41. Gilead's Next Hepatitis C Drug A Hit In Trials

    IBD
  42. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  43. UPDATE: Morgan Stanley Reiterates on AbbVie After Competitor's Schizophrenia ...

    Benzinga
  44. Drug trials cut new FDA path

    IBD
  45. Gilead knocked on drug price

    IBD
  46. Gilead HCV Drug May Face Price War; Rival AbbVie Up

    IBD
  47. Gilead Potential Blockbuster Hep C Drug Wins FDA Nod

    IBD
  48. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD
  49. Market Wrap For December 3: Markets Finish In The Red For Third Straight ...

    Benzinga
  50. After Top-Seller Remicade: Analysis of J&J’s Future

    YCharts
Trading Center